Bruker completes acquisition of Varian’s Accel Instruments subsidiary

Pursuant to the terms of the acquisition, Varian is retaining the proton therapy business, which will now operate as Varian Particle Therapy, while Bruker has acquired substantially all of the assets of the research instruments (RI) business. Financial terms of the transaction were not disclosed.

The RI business acquired by Bruker includes electron and ion LINACs, superconducting and normal conducting accelerator cavities, insertion devices, other accelerator components, neutron source subunits, specialized superconducting magnets, superconducting devices, X-ray and particle beamlines, as well as vacuum and cryosystems.

Bruker has retained Udo Klein and Michael Peiniger as managing directors and minority shareholders in the newly acquired RI business, which has been sub-divided into two new Bruker subsidiaries: RI Research Instruments and Bruker Advanced Supercon.

RI Research Instruments will focus on rf cavities and systems, linear accelerators, and special products for physics and energy research. It is 45% owned by its management team, and 55% by Bruker.

Bruker Advanced Supercon will focus on low and high temperature superconducting devices, circular accelerator vacuum systems, beamlines, and X-ray optics businesses, as well as specialty superconducting magnets for physics, energy research, medical devices, crystal growth applications, etc. It is 100% owned by Bruker.

Burkhard Prause, CEO of Bruker Advanced Supercon, said: “This acquisition opens an important new chapter in the history of our Bruker Advanced Supercon business. It positions us for rapid revenue and margin growth in several exciting markets, including renewable energy research, the more stable and energy efficient electricity grids of the future, next-generation materials research and manufacturing, as well as components for cutting-edge medical devices.”